It’s only fair to share… Admilparant, (BMS-986278) CAS 2170126-74-4 MF C22H31N5O5 MW 445.5 g/mol (1S,3S)-3-({2-methyl-6-[1-methyl-5-({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-l]pyridin-3-yl}oxy)cyclohexane-1-carboxylic acidlysophosphatidic acid receptor 1 (LPA1) antagonist Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist.[1][2] As of 2024, admilparant is in Phase III clinical trials …